Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1990 1
2002 3
2004 5
2005 5
2006 6
2007 4
2008 1
2009 3
2010 10
2011 12
2012 15
2013 7
2014 7
2015 15
2016 12
2017 11
2018 8
2019 20
2020 15
2021 17
2022 8
2023 6

Text availability

Article attribute

Article type

Publication date

Search Results

160 results

Results by year

Filters applied: . Clear all
Page 1
SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial.
Rothschild SI, Zippelius A, Eboulet EI, Savic Prince S, Betticher D, Bettini A, Früh M, Joerger M, Lardinois D, Gelpke H, Mauti LA, Britschgi C, Weder W, Peters S, Mark M, Cathomas R, Ochsenbein AF, Janthur WD, Waibel C, Mach N, Froesch P, Buess M, Bohanes P, Godar G, Rusterholz C, Gonzalez M, Pless M; Swiss Group for Clinical Cancer Research (SAKK). Rothschild SI, et al. Among authors: joerger m. J Clin Oncol. 2021 Sep 10;39(26):2872-2880. doi: 10.1200/JCO.21.00276. Epub 2021 Jul 12. J Clin Oncol. 2021. PMID: 34251873 Free article. Clinical Trial.
Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade.
Berner F, Bomze D, Lichtensteiger C, Walter V, Niederer R, Hasan Ali O, Wyss N, Bauer J, Freudenmann LK, Marcu A, Wolfschmitt EM, Haen S, Gross T, Abdou MT, Diem S, Knöpfli S, Sinnberg T, Hofmeister K, Cheng HW, Toma M, Klümper N, Purde MT, Pop OT, Jochum AK, Pascolo S, Joerger M, Früh M, Jochum W, Rammensee HG, Läubli H, Hölzel M, Neefjes J, Walz J, Flatz L. Berner F, et al. Among authors: joerger m. Sci Immunol. 2022 Sep 2;7(75):eabn9644. doi: 10.1126/sciimmunol.abn9644. Epub 2022 Sep 2. Sci Immunol. 2022. PMID: 36054337
How to read a next-generation sequencing report-what oncologists need to know.
Schmid S, Jochum W, Padberg B, Demmer I, Mertz KD, Joerger M, Britschgi C, Matter MS, Rothschild SI, Omlin A. Schmid S, et al. Among authors: joerger m. ESMO Open. 2022 Oct;7(5):100570. doi: 10.1016/j.esmoop.2022.100570. Epub 2022 Sep 29. ESMO Open. 2022. PMID: 36183443 Free PMC article. Review.
Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors.
Nuñez NG, Berner F, Friebel E, Unger S, Wyss N, Gomez JM, Purde MT, Niederer R, Porsch M, Lichtensteiger C, Kramer R, Erdmann M, Schmitt C, Heinzerling L, Abdou MT, Karbach J, Schadendorf D, Zimmer L, Ugurel S, Klümper N, Hölzel M, Power L, Kreutmair S, Capone M, Madonna G, Cevhertas L, Heider A, Amaral T, Hasan Ali O, Bomze D, Dimitriou F, Diem S, Ascierto PA, Dummer R, Jäger E, Driessen C, Levesque MP, van de Veen W, Joerger M, Früh M, Becher B, Flatz L. Nuñez NG, et al. Among authors: joerger m. Med. 2023 Feb 10;4(2):113-129.e7. doi: 10.1016/j.medj.2022.12.007. Epub 2023 Jan 23. Med. 2023. PMID: 36693381 Free article.
C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer.
Klümper N, Saal J, Berner F, Lichtensteiger C, Wyss N, Heine A, Bauernfeind FG, Ellinger J, Brossart P, Diem S, Schmid S, Joerger M, Frueh M, Ritter M, Hölzel M, Flatz L, Bald T. Klümper N, et al. Among authors: joerger m. J Immunother Cancer. 2022 Mar;10(3):e004024. doi: 10.1136/jitc-2021-004024. J Immunother Cancer. 2022. PMID: 35292517 Free PMC article.
Radiotherapy for thymic epithelial tumours: a review.
Süveg K, Putora PM, Joerger M, Iseli T, Fischer GF, Ammann K, Glatzer M. Süveg K, et al. Among authors: joerger m. Transl Lung Cancer Res. 2021 Apr;10(4):2088-2100. doi: 10.21037/tlcr-20-458. Transl Lung Cancer Res. 2021. PMID: 34012817 Free PMC article. Review.
Gemcitabine-associated hemolytic-uremic syndrome.
Walter RB, Joerger M, Pestalozzi BC. Walter RB, et al. Among authors: joerger m. Am J Kidney Dis. 2002 Oct;40(4):E16. doi: 10.1053/ajkd.2002.35758. Am J Kidney Dis. 2002. PMID: 12324937 Review.
Tumour neoantigen mimicry by microbial species in cancer immunotherapy.
Boesch M, Baty F, Rothschild SI, Tamm M, Joerger M, Früh M, Brutsche MH. Boesch M, et al. Among authors: joerger m. Br J Cancer. 2021 Aug;125(3):313-323. doi: 10.1038/s41416-021-01365-2. Epub 2021 Apr 6. Br J Cancer. 2021. PMID: 33824481 Free PMC article. Review.
Treatment regimens of classical and newer taxanes.
Joerger M. Joerger M. Cancer Chemother Pharmacol. 2016 Feb;77(2):221-33. doi: 10.1007/s00280-015-2893-6. Epub 2015 Nov 20. Cancer Chemother Pharmacol. 2016. PMID: 26589792 Review.
160 results